Skip to main content

Lasers Improve Phototherapy-Drug Delivery Platform






Photoimmunotherapy targets cancer cells with microscopic, nano-engineered cancer drugs that are light-activated at the lesion site. Although the technology is increasingly used to treat metastatic cancer, tools to improve the effectiveness of photoimmunotherapy in gynecologic oncology have been lacking. Responses to treatment vary from person to person, and no method has existed to readily monitor whether the drugs are delivered effectively or have the desired therapeutic effect.

Researchers from the University of Maryland (UMD), in collaboration with medical laser manufacturer Modulight, demonstrated that the efficacy, safety, and consistency of photoimmunotherapy can be improved by integrating targeted, light-based techniques for drug delivery with laser-assisted endoscopy and fluorescence-guided treatment planning.

The researchers designed a drug delivery system using targeted, photo-activable, multi-agent liposomes (TPMAL). TPMAL consists of chemotherapy drugs that are labeled with fluorescent markers. It improves therapeutic delivery and monitors the growth of metastases in difficult-to-treat locations within the body.

A laser-assisted endoscopic camera created by Modulight captures and uploads information from TPMAL to Modulight Cloud, a cloud services platform. Modulight Cloud analyzes the multispectral fluorescence emission from TPMAL in real time to enable fluorescence-guided drug delivery and fluorescence-guided light dosimetry. The real-time connectivity enables simultaneous treatment monitoring, remote protocol development, and rapid transfer and viewing of data.

The data acquired by the camera can be used to customize fluorescence-guided therapy. Doctors can use the data to determine, in real time, how well the drug-carrying liposomes are reaching and delivering treatment to metastatic cancer sites. They can also use the data to calculate the precise amount of laser light needed during photoimmunotherapy to minimize tissue damage.

The optimal accumulation of TPMAL in tumors can occur at different times for different patients. Fluorescence-guided drug delivery identifies the time when the TPMAL fluorescence signal is near peak levels in tumors, thereby informing the initiation of photoimmunotherapy for the best outcome.

The TPMAL levels in tumors can vary among patients. Fluorescence-guided light dosimetry monitors the photobleaching of photosensitizers during photoimmunotherapy, so that the light dose can be adjusted accordingly, in real time, to improve the consistency of treatment effects.

“Patients undergoing cancer treatment exhibit varying tolerances and individualized responses,” said UMD professor Huang Chiao Huang. “Through continuous monitoring of their progress, we can promptly determine if treatment adjustments are needed while they are actively receiving care. There is no need to postpone decisions until the next scheduled session.”

The researchers demonstrated their approach in mouse models with peritoneal carcinomatosis, a type of cancer that can be caused by metastatic ovarian cancer. They observed a fourteenfold improvement in drug delivery to metastatic tumors. The information captured by the endoscopic camera prompted fluorescence-guided light dosimetry in over 50% of the mice. By combining TPMAL, laser-assisted imaging, and fluorescence-guided intervention, the researchers achieved a more homogeneous response to treatment in the mice and improved tumor control without causing side effects.

Although nearly half of the women with advanced ovarian cancer achieve complete remission after surgery and chemotherapy, many patients will relapse due largely to residual submillimeter lesions. These residual micro-metastases are difficult to detect and often develop resistance to standard treatments. New approaches are needed to address these drug-resistant micro-metastases.

The UMD-Modulight study shows that a combination of targeted photomedicine drug delivery, imaging, and monitoring of treatment responses can help prevent the return and spread of cancer while minimizing the side effects of treatment. Together, the three techniques can give doctors the ability to make immediate adjustments in treatment to achieve better outcomes.

“This approach ensures that the treatment remains both effective and uniform,” Huang said. “This process is repeated as necessary for each patient, resulting in a personalized dosage tailored to maximize treatment effectiveness within a single session.”

The team is now working to establish a comprehensive panel of biomarkers that would allow doctors to promptly determine the optimal dosage for each patient during a treatment session.

“The goal is to minimize the number of treatment cycles required while minimizing burden on the patient’s body, in contrast to conventional treatment approaches,” Huang said.

Bio Photonics Research Award


Visit: biophotonicsresearch.com
Nominate Now: https://biophotonicsresearch.com/award-nomination/?ecategory=Awards&rcategory=Awardee

#MeatAnalysis #FluorescenceTech #FoodQuality #FoodSafety #SpectroscopyInFood #MeatAuthentication #RapidDetection #FoodScience #MeatFreshness #MolecularDetection #FoodIndustryInnovation #NonDestructiveTesting #FoodMonitoring #SpectroscopyApplications #QualityControl #AdvancedSpectroscopy #MeatSpoilageDetection #FoodIntegrity #SmartFoodTesting #RealTimeAnalysis #FoodAuthenticity #FoodSafetyInnovation #SpectroscopyResearch #NextGenFoodSafety #InnovativeFoodScience,

Comments

Popular posts from this blog

Abrisa Technologies Acquires Agama Glass Technologies

SANTA PAULA, Calif. — Abrisa Technologies, a provider of custom glass optics and thin film coatings and a subsidiary of HEF Photonics, has acquired Agama Glass Technologies, a manufacturer of etched anti-glare glass and technical glass processing. The acquisition, Abrisa said, expands its manufacturing footprint and adds a vertically integrated solution for chemically etched anti-glare display glass. According to Abrisa, Clarksburg, West Virginia-based Agama operates North America’s only high-volume technical glass etching facility. Agama's flagship product, AgamaEtch, is used in high-performance display and optics applications. The company's 85,000 sq ft facility also offers precision glass fabrication, chemical strengthening, and silk-screen printing, serving markets such as avionics, defense, medical, industrial, and touchscreen displays. Combined with Abrisa Technologies’ and HEF Photonics’ thin-film coating and surface engineering capabilities, Agama's offerings wi...

How Biophotonics Is Harnessing Light for Health And Science

Fifty or so years ago French physicist Pierre Aigrain coined the term photonics as a research field whose goal was to use light to perform functions that traditionally fell within the typical domain of electronics, such as telecommunications, and information processing. Or maybe it was John Campbell who, in a letter sent to Gotthard Gunther in 1954, wrote, “Incidentally, I’ve decided to invent a new science — photonics. It bears the same relationship to Optics that electronics does to electrical engineering. Photonics, like electronics, will deal with the individual units; optics and EE deal with the group phenomena! And note that you can do things with electronics that are impossible in electrical engineering!” Naming rights aside, the field of photonics began in earnest between 1958 and 1960 with the invention of the maser and the laser. The laser diode followed during the 1970s, optical fibers and the erbium-doped fiber amplifier after that, and, pretty soon, the telecommunications...

Laser Method Enables Fast & Precise Blood Vessels in Hydrogel

Researchers from Vienna University of Technology (TU Wien) and Keio University have found a way to create artificial blood vessels in miniature organ models in a quick and reproducible manner. The method utilizes ultrashort laser pulses in the femtosecond range to write highly 3D structures into a hydrogel. In biomedical research, organs-on-a-chip are becoming increasingly important: By cultivating tissue structures in precisely controlled microfluidic chips, it is possible to conduct research much more accurately than in experiments involving living humans or animals. However, there has been a major obstacle: such mini-organs are incomplete without blood vessels. To facilitate systematic studies and ensure meaningful comparisons with living organisms, a network of perfusable blood vessels and capillaries must be created — in a way that is precisely controllable and reproducible. “We can create channels spaced only a hundred micrometers apart. That’s essential when you would like to...